In addition, we have experience with pCR cases after pembrolizumab treatment in chemo-resistant UTUC patient, and analysis of the tumor microenvironment in these pCR specimens showed increasing CD8+ T cell and CD20+ cell20, suggesting that immune checkpoint inhibitors and platinum drugs may alter the tumor microenvironment differently. This evidence concerns the gene CD8A and neoplasm.